Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 4 of 4
Full-Text Articles in Medicine and Health Sciences
Alzheimer's Disease: A Journey From Amyloid Peptides And Oxidative Stress, To Biomarker Technologies And Disease Prevention Strategies-Gains From Aibl And Dian Cohort Studies, Ralph Martins, Victor Villemagnen, Hamid R. Sohrabi, Pratishtha Chatterjee, Tejal M. Shah, Giuseppe Verdile, Paul Fraser, Kevin Taddei, Veer Gupta, Stephanie Rainey-Smith, Eugene Hone, Steve Pedrini, Wei L. Lim, Ian Martins, Shaun Frost, Sunil Gupta, Sid O’Bryant, Alan Rembach, David Ames, Kathryn Ellis, Stephanie J. Fuller, Belinda Brown, Samantha Gardener, Binosha Fernando, Prashant Bharadwaj, Samantha Burnham, Simon Laws, Anna M. Barron, Kathryn Goozee, Eka J. Wahjoepramono, Prita R. Asih, James D. Doecke, Olivier Salvado, Ashley I. Bush, Christopher C. Rowe, Samuel E. Gandy, Colin L. Masters
Alzheimer's Disease: A Journey From Amyloid Peptides And Oxidative Stress, To Biomarker Technologies And Disease Prevention Strategies-Gains From Aibl And Dian Cohort Studies, Ralph Martins, Victor Villemagnen, Hamid R. Sohrabi, Pratishtha Chatterjee, Tejal M. Shah, Giuseppe Verdile, Paul Fraser, Kevin Taddei, Veer Gupta, Stephanie Rainey-Smith, Eugene Hone, Steve Pedrini, Wei L. Lim, Ian Martins, Shaun Frost, Sunil Gupta, Sid O’Bryant, Alan Rembach, David Ames, Kathryn Ellis, Stephanie J. Fuller, Belinda Brown, Samantha Gardener, Binosha Fernando, Prashant Bharadwaj, Samantha Burnham, Simon Laws, Anna M. Barron, Kathryn Goozee, Eka J. Wahjoepramono, Prita R. Asih, James D. Doecke, Olivier Salvado, Ashley I. Bush, Christopher C. Rowe, Samuel E. Gandy, Colin L. Masters
Research outputs 2014 to 2021
Worldwide there are over 46 million people living with dementia, and this number is expected to double every 20 years reaching about 131 million by 2050. The cost to the community and government health systems, as well as the stress on families and carers is incalculable. Over three decades of research into this disease have been undertaken by several research groups in Australia, including work by our original research group inWestern Australia which was involved in the discovery and sequencing of the amyloid-β peptide (also known as Aβ or A4 peptide) extracted from cerebral amyloid plaques. This review discusses the …
A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr
A Diagnostic Autoantibody Signature For Primary Cutaneous Melanoma, Pauline Zaenker, Johnny Lo, Robert L. Pearce, Phillip Cantwell, Lester Cowell, Mark Lee, Christopher Quirk, Henry Law, Elin S. Gray, Mel R. Ziman Dr
Research outputs 2014 to 2021
Melanoma is an aggressive form of skin cancer that is curable by surgical excision in the majority of cases, if detected at an early stage. To improve early stage melanoma detection, the development of a highly sensitive diagnostic test is of utmost importance. Here we aimed to identify antibodies to a panel of tumour associated antigens that can differentiate primary melanoma patients and healthy individuals. A total of 245 sera from primary melanoma patients and healthy volunteers were screened against a high-throughput microarray platform containing 1627 functional proteins. Following rigorous statistical analysis, we identified a combination of 10 autoantibody biomarkers …
Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang
Unravelling Immunoglobulin G Fc N-Glycosylation: A Dynamic Marker Potentiating Predictive, Preventive And Personalised Medicine, Alyce Russell, Eric Adua, Ivo Ugrina, Simon Laws, Wei Wang
Research outputs 2014 to 2021
Multiple factors influence immunoglobulin G glycosylation, which in turn affect the glycoproteins’ function on eliciting an anti-inflammatory or pro-inflammatory response. It is prudent to underscore these processes when considering the use of immunoglobulin G N-glycan moieties as an indication of disease presence, progress, or response to therapeutics. It has been demonstrated that the altered expression of genes that encode enzymes involved in the biosynthesis of immunoglobulin G N-glycans, receptors, or complement factors may significantly modify immunoglobulin G effector response, which is important for regulating the immune system. The immunoglobulin G N-glycome is highly heterogenous; however, it is …
Melanoma Circulating Tumor Cells: Benefits And Challenges Required For Clinical Application, G. Marsavela, Carlos A. Aya-Bonilla, M. E. Warkiani, Elin S. Gray, Mel R. Ziman
Melanoma Circulating Tumor Cells: Benefits And Challenges Required For Clinical Application, G. Marsavela, Carlos A. Aya-Bonilla, M. E. Warkiani, Elin S. Gray, Mel R. Ziman
Research outputs 2014 to 2021
The implementation of novel therapeutic interventions has improved the survival rates of melanoma patients with metastatic disease. Nonetheless, only 33% of treated cases exhibit long term responses. Circulating tumor cell (CTC) measurements are currently of clinical value in breast, prostate and colorectal cancers. However, the clinical utility of melanoma CTCs (MelCTCs) is still unclear due to challenges that appear intrinsic to MelCTCs (i.e. rarity, heterogeneity) and a lack of standardization in their isolation, across research laboratories. Here, we review the latest developments, pinpoint the challenges in MelCTC isolation and address their potential role in melanoma management.